U.S. Population Classified as ‘Immunocompromised’ Explodes Higher, in Latest JAMA Report.

New report nearly doubles the GeoVax addressable market of Immunocompromised Patients (i.e. potential customers) from 15 Million, to 23 Million patients! Not updated were the estimated 260 million people worldwide, who have weakened immune systems.

Conference Call Tonight.

GeoVax has a vaccine in Phase II clinical trials in the U.S. for the immunocompromised, called MVA-VLP or ‘EmVeeAye.’ If approved by the FDA – it would no doubt become available internationally.

In the recently released report From the Journal of American Medicine, the report revealed the previous calculations we’re based on data collected from 2013, while the new calculation was based on data from 2021.

The data was collected using ‘reported health condition’ factors such as such as having been diagnosed with an immunosuppressive condition, taking immunosuppressive medications, or having cancer. Missing from the data were those who are diabetic and the obese.

Journal of American Medicine: Prevalence of Immunosuppression Among US Adults

At a guesstimated price of $50 per treatment, this translates to a shot on goal (they have six) valued in the U.S. alone of $1.3 billion, or $2.6 billion if priced at $100.

Of course they won’t see dollar one, if it isn’t approved by the FDA. And no drugs, no matter how effective reach their full addressable market. But it’s a long way from a $6 million market capitalization to any of those above numbers. A long way.

February 29th, 2024: CDC Experts Recommend Seniors Get Another COVID Shot.

“Given the risk of severe, even life-threatening, disease, I would encourage those who are moderately to severely immunocompromised to take the opportunity for another dose.” Dr. Camille Kotton, a physician at Massachusetts General Hospital.

CNN: Millions of Immunocompromised Americans Might not Have had an Adequate Response to the Covid-19 Vaccine

“June Tatelman recently received her second dose of Pfizer’s Covid-19 vaccine. Her doctor had been reading recent medical studies suggesting the vaccine might not work well for some people taking medications like hers. He asked her to get a blood test to see if the vaccine had worked – if she had antibodies against the virus.

She did the test and had no detectable antibodies against Covid-19. “It was a total shock,” she said.


GeoVax News Archive

GeoVax Live Quote

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. GOVX is a client of Institutional Analyst which receives a monthly retainer of five-thousand dollars for ongoing progress reporting and news coverage.